bupropion has been researched along with Frigidity in 48 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants." | 9.09 | Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001) |
| " We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants." | 5.09 | Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001) |
| "Outpatients with moderate to severe major depressive disorder (DSM-IV) received bupropion SR (100-300 mg/day) or sertraline (50-200 mg/day) for 16 weeks." | 5.08 | Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. ( Ascher, JA; Hughes, AR; Johnston, JA; Kavoussi, RJ; Segraves, RT, 1997) |
| " Bupropion is less likely than other antidepressants to cause weight gain and sexual dysfunction, the 2 side effects that are of greatest concern to patients and that have the greatest impact on long-term compliance." | 4.82 | Why isn't bupropion the most frequently prescribed antidepressant? ( Attiullah, N; Baymiller, S; Berlowitz, SL; Boland, RJ; Chelminski, I; Friedman, M; Posternak, MA; Rahman, S; Singer, S; Uy, KK; Zimmerman, M, 2005) |
| "Bupropion was not more effective than placebo in improving the desire subscale of the FSFI." | 3.11 | Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004. ( Balcueva, EP; Barton, DL; Basil, JB; Bell, MC; Carter, J; Deshmukh, S; Ganz, PA; Greyz-Yusupov, N; Hill, ML; Kachnic, LA; Koontz, BF; Muller, CY; Nabeel, S; Page, SJ; Plaxe, SC; Pugh, SL; Rowland, KM, 2022) |
| "Prior medication treatment for hypoactive sexual desire disorder (HSDD) in women has left about half the subjects without benefit." | 2.90 | Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women. ( Clayton, AH; Pyke, RE, 2019) |
| " A meta-regression was performed to explore heterogeneity and we found that only the dosage of bupropion was statistically significant in explaining the variance, i." | 2.82 | The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis. ( Baharudin, A; Choy, CL; Das, S; Razali, NA; Roos, NAC; Sidi, H, 2022) |
| " A total of 218 women (25-45 years old) with SSRI-induced sexual dysfunction were randomized to receive 12 weeks of double-blind fixed dosed treatment with bupropion sustained release 150 mg b." | 2.76 | Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study. ( Safarinejad, MR, 2011) |
| "Bupropion is an effective treatment for male SD induced by SSRIs." | 2.75 | The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study. ( Safarinejad, MR, 2010) |
| "Bupropion is an antidepressant with fewer reported adverse sexual effects." | 2.70 | Effects of bupropion sustained-release on sexual functioning and nocturnal erections in healthy men. ( Arana, GW; Brodrick, PS; Labbate, LA; Lydiard, RB; Nelson, RP, 2001) |
| "The etiology of hypoactive sexual desire disorder is multifactorial and its management requires a combination of psychosocial and pharmacological interventions." | 2.47 | Managing low sexual desire in women. ( Maclaran, K; Panay, N, 2011) |
| "Antidepressant-induced adverse sexual effects are becoming more frequently reported by patients who require pharmacotherapy." | 2.39 | Sexual side effects of antidepressants: a review. ( Assalian, P; Margolese, HC, 1996) |
| "Major depressive disorder (MDD) and type 2 diabetes have independent adverse effects on sexual functioning (SF)." | 1.37 | Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion. ( Gott, BM; Lustman, PJ; Nix, BD; Sayuk, GS, 2011) |
| "Bupropion SR as a treatment for depression also alleviates sexual dysfunction due to SSRI treatment." | 1.31 | Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. ( Abouesh, AI; Clayton, AH; McGarvey, EL; Pinkerton, RC, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.08) | 18.7374 |
| 1990's | 13 (27.08) | 18.2507 |
| 2000's | 21 (43.75) | 29.6817 |
| 2010's | 10 (20.83) | 24.3611 |
| 2020's | 3 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Barton, DL | 1 |
| Pugh, SL | 1 |
| Ganz, PA | 1 |
| Plaxe, SC | 1 |
| Koontz, BF | 1 |
| Carter, J | 1 |
| Greyz-Yusupov, N | 1 |
| Page, SJ | 1 |
| Rowland, KM | 1 |
| Balcueva, EP | 1 |
| Nabeel, S | 1 |
| Basil, JB | 1 |
| Hill, ML | 1 |
| Muller, CY | 1 |
| Bell, MC | 1 |
| Deshmukh, S | 1 |
| Kachnic, LA | 1 |
| Razali, NA | 1 |
| Sidi, H | 1 |
| Choy, CL | 1 |
| Roos, NAC | 1 |
| Baharudin, A | 1 |
| Das, S | 1 |
| Pyke, RE | 1 |
| Clayton, AH | 5 |
| Ramli, FF | 1 |
| Azizi, MH | 1 |
| Syed Hashim, SA | 1 |
| Lodise, NM | 1 |
| Safarinejad, MR | 3 |
| Hosseini, SY | 1 |
| Asgari, MA | 1 |
| Dadkhah, F | 1 |
| Taghva, A | 1 |
| DeRogatis, LR | 1 |
| Sayuk, GS | 1 |
| Gott, BM | 1 |
| Nix, BD | 1 |
| Lustman, PJ | 1 |
| Maclaran, K | 1 |
| Panay, N | 1 |
| Calandra, C | 1 |
| Russo, RG | 1 |
| Luca, M | 1 |
| Hartmann, UH | 1 |
| Rüffer-Hesse, C | 1 |
| Krüger, TH | 1 |
| Philippsohn, S | 1 |
| Warnock, JK | 1 |
| Biggs, CF | 1 |
| Chollet, CA | 1 |
| Andreatini, R | 1 |
| Segraves, RT | 4 |
| Clayton, A | 1 |
| Croft, H | 2 |
| Wolf, A | 1 |
| Warnock, J | 1 |
| Zimmerman, M | 1 |
| Posternak, MA | 1 |
| Attiullah, N | 1 |
| Friedman, M | 1 |
| Boland, RJ | 1 |
| Baymiller, S | 1 |
| Berlowitz, SL | 1 |
| Rahman, S | 1 |
| Uy, KK | 1 |
| Singer, S | 1 |
| Chelminski, I | 1 |
| DeBattista, C | 1 |
| Solvason, B | 1 |
| Poirier, J | 1 |
| Kendrick, E | 1 |
| Loraas, E | 1 |
| Menaster, MJ | 1 |
| Dobkin, RD | 1 |
| Menza, M | 1 |
| Marin, H | 1 |
| Allen, LA | 1 |
| Rousso, R | 1 |
| Leiblum, SR | 1 |
| Basson, R | 1 |
| Brotto, LA | 1 |
| Laan, E | 1 |
| Redmond, G | 1 |
| Utian, WH | 1 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Croft, HA | 1 |
| Horrigan, JP | 1 |
| Wightman, DS | 1 |
| Krishen, A | 1 |
| Richard, NE | 1 |
| Modell, JG | 2 |
| Montejo, AL | 1 |
| Thase, ME | 1 |
| Haight, BR | 1 |
| Thompson, AH | 1 |
| Johnston, JA | 3 |
| Jefferson, JW | 1 |
| Segraves, KB | 1 |
| Bubna, CN | 1 |
| Walker, PW | 1 |
| Cole, JO | 1 |
| Gardner, EA | 1 |
| Hughes, AR | 2 |
| Batey, SR | 3 |
| Lineberry, CG | 1 |
| Margolese, HC | 1 |
| Assalian, P | 1 |
| Kavoussi, RJ | 1 |
| Ascher, JA | 3 |
| Labbate, LA | 3 |
| Grimes, JB | 1 |
| Hines, A | 1 |
| Pollack, MH | 1 |
| Ashton, AK | 2 |
| Rosen, RC | 1 |
| Dewan, MJ | 1 |
| Anand, VS | 1 |
| Settle, E | 1 |
| Houser, T | 1 |
| Donahue, RM | 2 |
| Hirschfeld, RM | 1 |
| Coleman, CC | 1 |
| Cunningham, LA | 1 |
| Foster, VJ | 1 |
| Houser, TL | 1 |
| Ramasubbu, R | 1 |
| Brodrick, PS | 1 |
| Nelson, RP | 1 |
| Lydiard, RB | 1 |
| Arana, GW | 1 |
| Zajecka, J | 1 |
| Ferguson, JM | 1 |
| McGarvey, EL | 1 |
| Abouesh, AI | 1 |
| Pinkerton, RC | 1 |
| Masand, PS | 1 |
| Gupta, S | 1 |
| Frank, B | 1 |
| Chengappa, KN | 1 |
| Kambhampati, RK | 1 |
| Perkins, K | 1 |
| Nigam, R | 1 |
| Anderson, T | 1 |
| Brar, JS | 1 |
| Vemulapalli, HK | 1 |
| Atzert, R | 1 |
| Key, P | 1 |
| Kang, JS | 1 |
| Levine, J | 1 |
| Hierholzer, R | 1 |
| Crenshaw, TL | 1 |
| Goldberg, JP | 1 |
| Stern, WC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer[NCT03180294] | Phase 2 | 230 participants (Actual) | Interventional | 2017-05-31 | Completed | ||
| A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Exte[NCT00316160] | Phase 4 | 347 participants | Interventional | 2004-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as sexual desire in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 weeks from start of study treatment (within 21 days of randomization)
| Intervention | units on a scale (Mean) |
|---|---|
| Bupropion 150 mg | 0.70 |
| Bupropion 300 mg | 0.48 |
| Placebo | 0.58 |
"The desire subscore of the female sexual function index (FSFI) measures self-reported sexual desire. Possible scores range from 1.2 to 6, with higher scores indicating increased desire. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased desire. This measure is referred to as sexual desire in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 9 weeks from start of study treatment (within 21 days of randomization)
| Intervention | units on a scale (Mean) |
|---|---|
| Bupropion 150 mg | 0.64 |
| Bupropion 300 mg | 0.60 |
| Placebo | 0.62 |
Common Terminology Criteria for Adverse Events (version 4) grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure.; see Adverse Events Module for specific adverse event data. (NCT03180294)
Timeframe: Adverse events were evaluated 1,2,5,7, and 9 weeks from start of study treatment (within 21 days of randomization).
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupropion 150 mg | 4 |
| Bupropion 300 mg | 1 |
| Placebo | 3 |
"The FSFI total score measures self-reported female sexual functioning covering the major domains arousal, satisfaction, and orgasm, and including lubrication and pain. Possible scores range from 2 to 36, with higher scores indicating better functioning. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased functioning. This measure is referred to as sexual functioning in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 5 | Week 9 | |
| Bupropion 150 mg | 3.84 | 3.29 |
| Bupropion 300 mg | 4.01 | 3.55 |
| Placebo | 3.53 | 4.70 |
"The PHQ-4 is a brief screening questionnaire for depression. Possible scores range from 0 to 12, with higher scores indicating more severe depression. Change score is calculated by subtracting baseline from later score, with a negative change score indicating decreased severity of depression. This measure is referred to as depressive mood in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of treatment (within 21 days of randomization)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 5 | Week 9 | |
| Bupropion 150 mg | -0.44 | -0.42 |
| Bupropion 300 mg | -0.17 | -0.43 |
| Placebo | -0.16 | -0.43 |
"The PROMIS Global Satisfaction with Sex Life subscore measures self-reported global satisfaction, interest, and interference in sexual health over the past 7 days. Possible scores range from 3 to 30, with higher scores indicating more satisfaction with sex life. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased satisfaction. This score is referred to as the PROMIS sexual desire and satisfaction measure in the protocol." (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 5 | Week 9 | |
| Bupropion 150 mg | 3.35 | 2.05 |
| Bupropion 300 mg | 2.81 | 2.72 |
| Placebo | 3.08 | 3.58 |
The PROMIS fatigue score measures self-reported fatigue symptoms over the past 7 days. Possible scores range from 33.1 to 77.8, with higher scores indicating more fatigue. Change score is calculated by subtracting baseline from later score, with a positive change score indicating increased fatigue. (NCT03180294)
Timeframe: Baseline (prior to randomization) and 5 and 9 weeks from start of study treatment (within 21 days of randomization)
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 5 | Week 9 | |
| Bupropion 150 mg | -2.29 | -3.28 |
| Bupropion 300 mg | -1.11 | -3.14 |
| Placebo | -0.30 | -3.42 |
Questions refer to the participants' experiences for the past 7 days of a given symptom in terms of frequency (never, rarely, occasionally, frequently, almost constantly), severity (none, mild, moderate, severe, very severe), interference with usual or daily activities (not at all, a little bit, somewhat, quite a bit, very much). (NCT03180294)
Timeframe: 9 weeks from start of study treatment (within 21 days of randomization).
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severity of dry mouth at its worst = very severe | Severity of decreased appetite at its worst= very severe | Interference of decreased appetite with usual or daily activities = very much | Frequency of nausea = almost constantly | Severity of nausea at its worst = very severe | Severity of constipation at its worst = very severe | Severity of dizziness at its worst = very severe | Interference of dizziness with usual or daily activities = very much | Frequency of headache = almost constantly | Severity of headache at its worst = very severe | Interference of headache with usual or daily activities = very much | Severity of insomnia at it's worst = very severe | Interference of insomnia with usual or daily activities = very much | |
| Bupropion 150 mg | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bupropion 300 mg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Placebo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
"Participants are asked, Were the benefits of this treatment greater than any side effects?" (NCT03180294)
Timeframe: 9 weeks from start of study treatment (within 21 days of randomization)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| No | Yes | |
| Bupropion 150 mg | 37 | 30 |
| Bupropion 300 mg | 32 | 26 |
| Placebo | 40 | 21 |
12 reviews available for bupropion and Frigidity
| Article | Year |
|---|---|
The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis.
Topics: Bupropion; Female; Humans; Libido; Sexual Dysfunctions, Psychological; Treatment Outcome | 2022 |
Treatments of Sexual Dysfunction in Opioid Substitution Therapy Patients: A Systematic Review and Meta-Analysis.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Humans; Opiate Substitution Treatment; Panax; P | 2021 |
Hypoactive sexual desire disorder in women: treatment options beyond testosterone and approaches to communicating with patients on sexual health.
Topics: alpha-MSH; Antidepressive Agents, Second-Generation; Benzimidazoles; Bupropion; Complementary Therap | 2013 |
Managing low sexual desire in women.
Topics: Bupropion; Dopamine Uptake Inhibitors; Education, Medical, Continuing; Female; Humans; Libido; Menop | 2011 |
Why isn't bupropion the most frequently prescribed antidepressant?
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; | 2005 |
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Delayed-Act | 2006 |
Major depressive disorder, antidepressants, and sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; B | 2006 |
Sexual side effects of antidepressants: a review.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Bupropion; Female; Humans; Libido; Male; Moclobemide; | 1996 |
Antidepressant-induced sexual dysfunction.
Topics: Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Libido; | 1998 |
Care of the sexually active depressed patient.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Tria | 1999 |
Strategies for the treatment of antidepressant-related sexual dysfunction.
Topics: Antidepressive Agents; Bupropion; Buspirone; Central Nervous System Stimulants; Depressive Disorder; | 2001 |
The effects of antidepressants on sexual functioning in depressed patients: a review.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 2001 |
19 trials available for bupropion and Frigidity
| Article | Year |
|---|---|
Randomized Controlled Phase II Evaluation of Two Dose Levels of Bupropion Versus Placebo for Sexual Desire in Female Cancer Survivors: NRG-CC004.
Topics: Adult; Aged; Breast Neoplasms; Bupropion; Cancer Survivors; Delayed-Action Preparations; Dopamine Up | 2022 |
Dose-Finding Study of Lorexys for Hypoactive Sexual Desire Disorder in Premenopausal Women.
Topics: Adult; Bupropion; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; | 2019 |
The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor: a double-blind placebo-controlled and randomized study.
Topics: Adult; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Epidemiologic Methods; Hum | 2010 |
Reversal of SSRI-induced female sexual dysfunction by adjunctive bupropion in menstruating women: a double-blind, placebo-controlled and randomized study.
Topics: Adult; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inhibitor | 2011 |
A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women.
Topics: Adult; Bupropion; Dopamine Uptake Inhibitors; Epidemiologic Methods; Female; Humans; Libido; Menstru | 2010 |
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder | 2012 |
Individual and dyadic barriers to a pharmacotherapeutic treatment of hypoactive sexual desire disorders: results and implications from a small-scale study with bupropion.
Topics: Adult; Arousal; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Dopamine Uptake I | 2012 |
Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women.
Topics: Adult; Bupropion; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Premenopause; Se | 2004 |
A placebo-controlled, randomized, double-blind study of adjunctive bupropion sustained release in the treatment of SSRI-induced sexual dysfunction.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Double-Blind Metho | 2005 |
Bupropion improves sexual functioning in depressed minority women: an open-label switch study.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depression; Dopamine Uptake Inhibitors; | 2006 |
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Delayed-Act | 2006 |
A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder, Majo | 2006 |
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Topics: 1-Naphthylamine; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Delayed | 1997 |
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
Topics: Adult; Aged; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inh | 1999 |
Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.
Topics: Adult; Aged; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Dopamine Uptake Inh | 1999 |
Effects of bupropion sustained-release on sexual functioning and nocturnal erections in healthy men.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cross-Over Studies; Delayed-Action Prepa | 2001 |
Sustained-release bupropion for selective serotonin reuptake inhibitor-induced sexual dysfunction: a randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Double-Blin | 2001 |
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Bupropion; Comorbidity; Delayed-Action Prepar | 2001 |
Pharmacologic modification of psychosexual dysfunction.
Topics: Adult; Bupropion; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Libido; Male; Middl | 1987 |
18 other studies available for bupropion and Frigidity
| Article | Year |
|---|---|
Consultation corner. The latest on female sexual health.
Topics: Adjuvants, Immunologic; Adult; Antidepressive Agents, Second-Generation; Atrophy; Benzimidazoles; Bu | 2010 |
Improvement in sexual functioning in patients with type 2 diabetes and depression treated with bupropion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Dep | 2011 |
Reproductive life events and sexual functioning in women: case reports.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Female; Hormone Replacement Therapy; Hum | 2003 |
Effect of bupropion on sexual dysfunction induced by fluoxetine: a case report of hypersexuality.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Interac | 2003 |
Weight gain, sexual dysfunction, and bupropion.
Topics: Ambulatory Care; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Labeling; Humans; | 2005 |
Assessment and management of women's sexual dysfunctions: problematic desire and arousal.
Topics: Adult; Androgens; Bupropion; Depression; Diagnostic and Statistical Manual of Mental Disorders; Dopa | 2005 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Drugs for female sexual dysfunction.
Topics: Bupropion; Estrogens; Female; Humans; Piperazines; Purines; Sexual Dysfunctions, Psychological; Sild | 2007 |
Psychotropic medications and their effects on sexual function.
Topics: Bupropion; Epilepsy; Female; Humans; Male; Psychotropic Drugs; Selective Serotonin Reuptake Inhibito | 1995 |
Sexual function in patients taking bupropion sustained release.
Topics: Bupropion; Humans; Sexual Behavior; Sexual Dysfunctions, Psychological | 1995 |
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Topics: Ambulatory Care; Bupropion; Depressive Disorder; Female; Fluoxetine; Humans; Libido; Male; Middle Ag | 1993 |
Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Anxiety Dis | 1997 |
Bupropion as an antidote for serotonin reuptake inhibitor-induced sexual dysfunction.
Topics: Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Dose-Response Relationship, Drug; Drug A | 1998 |
Bupropion-SR-induced increased libido and spontaneous orgasm.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bupr | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delaye | 1999 |
Bupropion treatment-related sexual side effects: a case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Female; Humans; Sexual Dysfunctions, Psy | 2000 |
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Delayed-Action Preparatio | 2001 |
Buproprion and sexual dysfunction.
Topics: Bupropion; Delayed-Action Preparations; Humans; Selective Serotonin Reuptake Inhibitors; Sexual Dysf | 2002 |